generation WATCHMAN LAA closure device. Of the 36 patients, the new device was implanted in 34 (94.4%). In two patients (5.6%), device closure was attempted but unsuccessful due to an unfavorable LAA anatomy (early separation into multiple lobes in one and acute LAA angulation in the second). In these cases closure was performed successfully with a different closure system. Though in eight patients partial and in fourteen full recaptures were needed prior to final release, there was no pericardial effusion. Mean procedural time was 50 AE 45 minutes. No device-related adverse events occurred during the procedure and accurate device placement was achieved in all implanted patients. During the follow-up of 12 months, three ischemic strokes (8.3%), one hemorrhage stroke (2.7%), one TIA (2.7%) and three deaths (8.7%) occurred. Device-associated thrombus formation was seen in one patient (2.7%) at the six-month follow-up treated with low molecular weight heparin. Conclusions: LAA closure with the newer (fourth) generation WATCHMAN device is feasible and safe. The atraumatic distal end may reduce the incidence of pericardial effusion during implantation.
Background: Hemodynamic changes after MitraClipÒ procedure are rarely described till today. Aim of this work was to improve the understanding of the acute hemodynamic effects. Methods: Till today more than 330 Patients have been treated with the MitraClipÒ System at the AK St. Georg in Hamburg. Hemodynamics have been evaluated with Swan Ganz catheterization and thermodilution method directly before and after Clipping. The functional result was assessed 6 weeks, 6 months and 12 months after the MitraClipÒ procedure.
Results: 314 out of 330(95.2%) patients could be treated successfully (MR post 2). 30 day mortality was 7%. MR was reduced significantly from 3.0(AE0.3) to 1.1(AE1.1) (p<0.001), needing an average of 1.4 Clips(AE0.6). Cardiac output(CO) increased from 3.7l/min(AE1.1) to 4.7l/min(AE1.3) directly after the procedure (p<0.001). Stroke volume(SV) increased from 62.4ml(AE18.7) to 80.7ml(AE26.9) (p<0.001). Systolic pulmonary artery pressure (PAPs) increased slightly from 39.9mmHg(AE12.5) to 42.2mmHg(AE12.2) (p<0.05). Wedge pressure (PCWP, mean) fell from 16.8mmHg(AE7.8) before to 15.7mmHg(AE6.5) post MitraClipÒ (p<0.05). Left atrial pressure (LA, mean) was reduced significantly (p<0.001) from 16.1mmHg(AE6.9) to 13.2mmHg(AE6.1). Grade of dyspnea by NYHA fell significantly as well (3.2(AE0.5) baseline, 2.1(AE0.7) after 6 months and 2.2(AE0.6) after 12 months), p<0.001. Grade of MR assessed by echo was reduced stable and significantly from 3.1(AE0.3) before to 1.1(AE0.6) directly after and 1.8(AE0.7) after 6 months, p<0.001.
Conclusions: The MitraClip procedure shows a stable reduction of MR combined with a stable improvement of the clinical symptom dyspnea. We've shown that this non open chest treatment of MR improves the CO and SV of up to 27% while reducing LA pressure significantly. If these findings have a prognostic impact is part of running investigation.
TCT-695
A Background: In Europe, MitraClip (MC) therapy for significant mitral regurgitation (MR) is increasingly being performed, particularly in elderly patients at high surgical risk. Outcomes emphasizing differences between men and women are lacking. We present a high-volume single-center retrospective analysis of outcomes according to gender. Methods: By 01/2013, 361 consecutive patients (75 AE 9 years, 227 men [M; 63%], 134 women [F; 37%]) with MR 3+/4+ had undergone MC therapy at the University Heart Center Hamburg. All patients were adjudicated by heart team consensus as not amenable to surgery. Results: Baseline conditions were significantly more adverse in M than in F, with higher log. EuroSCORE, lower LVEF, and higher prevalence of cardiomyopathy, hypercholesterolemia, diabetes, coronary artery disease, renal failure, and functional MR in the former. Procedures were successful (discharge MR 2+) in 207 M (91%) and 118 F (88%, p¼NS). Follow-up information was available in 205 M (90%) and 116 F (87%) at a median of 12.7 (range, 0.3-41) and 13.6 (0.4-39) months, respectively (p¼NS). No significant differences in the prevalence of MR 2+ and of NYHA functional class II were observed at 12 months (MR: M 91%, F 85%; NYHA: M 60%, F 50%) and 24 months (MR: M 91%, F 80%; NYHA: M 62%, F 49%). Overall, cumulative survival was not different between M and F (p[logrank]¼0.12), but survival curves diverged significantly in favor of F after 12 months (p¼0.03 by landmark analysis). Independent predictors of death on multivariate Cox regression analysis were renal failure and MC failure in M, yet renal failure and dilated cardiomyopathy in F. Rehospitalizations were frequent (M 54% and F 41% at 18 months), but not significantly different between M and F. MC failure was predictive of rehospitalizations in both genders. Conclusions: MC therapy appears to be equally effective, acutely as well as in the long term, in M and F at high surgical risk. Increased mortality after 1 year in M is likely related to higher comorbidity and poorer LV function and requires further study.
TCT-696
Pre-operative pro-BNP levels predict quality of life restoration 1 year after MitraClip treatment in heart failure patients with severe functional Mitral Regurgitation Background: The aim of this study is to investigate the predictors of quality of life (QoL) restoration 1 year after MitraClip implantation in heart failure patients with FMR in our single center experience. Methods: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69AE9 years). FMR was ischemic in 75%. All patients underwent standardized assessment of mitral valve anatomy and functional status. Preprocedural QoL was assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ). Logistic EuroScore was 22AE16%; 82% pts were in NYHA class III-IV. Mean EF was 28AE11%; LVEDD was 68AE8 mm. A cut-off of 14 points with MLHFQ was used to define QoL restoration 1 year after the procedure (corresponding to the mean MLHFQ observed in a NYHA I-II heart failure Italian population with mean age of 61 years). TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
Sydney, Sydney
Background: The MitraClip device has been used as a percutaneous therapy for both functional and degenerative mitral regurgitation (MR). However, the actual impact of the etiology of MR on safety and efficacy outcomes has not been well elucidated. We aim to describe the differences in experience and outcomes with the MitraClip in both functional and degenerative MR. Methods: The MitraClip Asia-Pacific Registry (MARS) registry is a multi-centre registry involving 6 different centres in the Asia-Pacific region (Singapore, Malaysia, Australia), collecting information on patients with !3+ MR who have undergone the MitraClip procedure. Primary efficacy outcome measured was a reduction in MR to 2+ at 30 days. The safety outcomes was 30-day freedom from major adverse events (MACE), including mortality, myocardial infarction, non-elective cardiac surgery for adverse events, renal failure, transfusion of !2 units of blood, ventilation for >48 h, septicaemia, and new onset of atrial fibrillation. Results: A total of 125 patients (age 71.8AE11.9years, 79 males) were included. Sixtyfour (51.2%) patients had functional MR and 61 (48.8%) had degenerative MR. Thirty one (48.4%) of functional MR patients had !2 clips inserted compared to 34 (56.7%) degenerative MR patients (p¼0.375). Acute procedural success was similar in both functional and degenerative MR (95.3% (61/64) vs 90.2% (55/61), p¼0.316). 71.9% (46/64) of functional MR had a reduction in MR to 2+ at 30 days compared to 70.5% (43/61) of degenerative MR (p¼0.510). There was no significant difference in both 30-day MACE (7.8% (n¼5) vs 14.8% (n¼9), p¼0.264) as well as 30-day mortality rates (4.7% (n¼3) vs 6.6% (n¼4), p¼0.713) between functional and degenerative MR. Conclusions: The MitraClip procedure has similarly good short-term efficacy and safety outcomes in the treatment of both functional and degenerative MR.
TCT-698
Acute changes in mitral annular geometery after Mitraclip procedure in functional and degenerative mitral regurgitation Jonathan Yap 1 , Khung Keong Yeo 1 , Nadira Hamid 1 , Eric Lim 1 , Peter Ting 1 , Hak Chiaw Tang 1 , See Hooi Ewe 2 , Zee Pin Ding 1 1 National Heart Centre Singapore, Singapore, Singapore, 2 National Heart Centre Singapore, s, s Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip device has been shown to be effective in reducing the severity of mitral regurgitation (MR), with resultant improvements in clinical outcomes. However, the actual changes in mitral annular geometry has not been well described. We aim to describe the effects of the MitraClip on the mitral annular geometry in both functional and degenerative mitral regurgitation Methods: 33 consecutive patients (age 72AE10 yr, 18 males) with !3+ MR, who underwent MitraClip procedure, were assessed with 3D transesophageal echocardiography before and immediately after the procedure. Specialised software (4D MV-Assessment, TomTec, GmbH) was used to process the images to obtain the following mitral annular parameters: anterior-posterior (AP) diameter, intercommissural diameter, 3D circumference (3D-C), 3D area (3D-A) and sphericity index (ratio of AP to intercommisural diameter). Results: Thirteen (39.4%) patients had functional MR and 20 (60.6%) had degenerative MR. Twenty seven (81.8%) patients had a !2-grade reduction in MR while the remainder had a 1-grade reduction. In patients with functional MR, there was a significant reduction in AP diameter (3.9AE0.5 vs 3.5AE0.4cm, p<0.001), intercommisural diameter (4.3AE0.4 vs 3.9AE0.5cm, p¼0.006), 3D-C (13.4AE1.3 vs 12.6AE1.3cm, p¼0.011) and 3D-A (13.7AE2.8 vs 11.5AE2.6cm2, p<0.001). There was no significant change in sphericity index. Similarly, in patients with degenerative MR, there was a significant reduction in AP diameter (3.8AE0.6 vs 3.4AE0.5cm, p<0.001), intercommisural diameter (4.2AE0.6 vs 3.7AE0.5cm, p<0.001), 3D-C (13.4AE1.9 vs 12.1AE1.4cm, p<0.001) and 3D-A (13.5AE3.8 vs 10.7AE2.6cm2, p<0.001). There was no significant change in sphericity index. Comparing patients with functional vs. degenerative MR, there was no significant difference in the degree of change for all the above parameters. Conclusions: Percutaneous edge-to-edge mitral valve repair results in acute changes in mitral annular geometry in both functional and degenerative MR. The actual impact of these geometrical changes on procedural success and durability of MR reduction requires further investigation.
TCT-699
MitraClip Therapy In Idiopathic Vs Ischemic Dilated Cardiomyopathy, A Single Center Experience. Background: MitraClip therapy is an emerging option for high-risk patients with functional mitral regurgitation (FMR). We compare MitraClip outcomes in idiopathic (ID) and ischemic (IS) MR. Methods: From October 2008, 109 patients underwent MitraClip for FMR at our Institution. All patients underwent a standardized prospective data collection pathway. Results: Patients were 27 ID (24.8%) and 82 IS (75.2%). Groups did not differ in age (p¼0.13), NYHA (p¼0.16) and pro-BNP (p¼0.47). ID were slightly "lowerrisk" due to less comorbidities: STS mortality 8.2% vs 11.5% (p¼0.06), REDO 3.2% vs 40.7% (p¼0.0004), COPD 11.1% vs 32.9 (p¼0.02), mean creatinine 1.3AE0.5 vs 1.65AE0.9 mg/dL(p¼0.04), inotropic support(0% vs 9.7%, p¼0.03). ID however had a more impaired QoL (mean MLHFQ 48AE16 vs 37AE13, p¼0.0008; SF36-F 29AE7 vs 35AE8, p¼0.004; SF36-M 38AE9 vs 39AE9; 6MWT 168AE76 vs 202AE109 m, p¼0.08) and a deeper heart dysfunction: mean EF 24AE9% vs 30AE11%, p¼0.02; EDD 69AE7 vs 67AE8 mm(p¼0.20). Implantation was successful in 100% vs 98.8%(p¼0.56) and multiple clips were used in 77.8% vs 67.1% (p¼0.19) of ID and IS respectively. Residual MR>2 was 11% vs 7.5% (p¼0.26). There was no difference in procedural time, post-operative length of stay and complications (all p>0.05). In-hospital mortality was 0% in ID vs 2 in IS patients (p¼0.41). Twenty-two ID and 64 IS reached 1-year follow-up: survival was 86.4% vs 90.6% (p¼0.57), MR 2 78% vs 80% (p¼0.81) respectively. Similar outcomes were also observed regarding NYHA (18% vs 9%, p¼0.26), MLHFQ (26AE17 vs 21AE17, p¼0.16), SF36-F (41AE11 vs 44AE9, p¼0.14), SF36-M (47AE11 vs 48AE10, p¼0.30) and 6MWT (336AE94 vs 329AE78, p¼0.59). All improvements were statistically significant compared to baseline, both in ID and IS (all p<0.05). At 1 year ID and IS had similar EDD (66AE10 vs 63AE8, p¼0.21), but improvement appeared significant only in the IS (p¼0.19 vs p¼0.0004). EF recovery was also reduced in the ID vs IS (26AE6 vs 36AE11, p¼0.0016; respectively p¼0.13 and p¼0.0036 against baseline). Conclusions: MitraClip in ID is safe and effective in MR reduction and symptoms relief at 1-year, providing similar outcomes compared to IS. Ventricle remodeling and EF recovery however appear to be reduced in the ID setting.
TCT-700
Percutaneous Vs Surgical Repair For Degenerative Mitral Regurgitation In Octogenarians.
Nicola Buzzatti 1 , Micaela Cioni 1 , Maurizio Taramasso 1 , Paolo Denti 1 , Antonio Colombo 2 , Giovanni La Canna 1 , Ottavio Alfieri 1 , Francesco Maisano 1 1 San Raffaele University Hospital, Milan, Italy, 2 EMO GVM Centro Cuore Columbus/ San Raffaele Hospital, Milan, Italy Background: MitraClip therapy is emerging as a viable option for high-risk patients. The aim of the study was to assess MitraClip and surgical repair results in octogenarians with degenerative mitral regurgitation (DMR). Methods: Since October 2008, 46 octogenarians underwent isolated mitral repair for DMR at our Institution using MitraClip or standard surgery. A retrospective comparison was conducted. Results: MitraClip was performed in 24 (52.2%) and surgery in 22 (44.8%) cases. Baseline features for MitraClip and surgery respectively included: mean age 84.7AE3.4 vs 81.8AE1.6 years (p¼0.0004), median STS mortality 8.4 vs 5.7 (p¼0.02), NYHA>II 70.8% vs 40.9% (p¼0.04), mean creatinine 1.2AE0.3 vs 0.9AE0.3 mg/dL (p¼0.009), chronic obstructive pulmonary disease 33% vs 9% (p¼0.04). The groups did not differ www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
